Related Experiment Video
Updated: Jul 19, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
A Rare Association of Hypomagnesemia and Posterior Reversible Encephalopathy Syndrome (PRES)
Alexander M Ball1, Appaji Rayi2, Mark Gustafson3
1Internal Medicine, Charleston Area Medical Center, Charleston, USA.
Abstract:
Posterior reversible encephalopathy syndrome (PRES) is a rare neurologic disorder that presents with variable symptoms and symmetrical abnormal white matter signaling most commonly of the occipital and parietal lobes on magnetic resonance imaging (MRI). PRES, also known as reversible posterior leukoencephalopathy syndrome (RPLS) is commonly associated with hypertension. Hypomagnesemia's association with PRES has been rarely reported. Here, we report a patient with severe hypomagnesemia that presented with PRES syndrome that improved with magnesium replacement. Hypomagnesemia should be considered an underlying etiology in patients presenting with PRES syndrome and should be promptly treated. The presentation can often be concerning for acute cerebrovascular accidents with symptoms of dysarthria and upper motor neuron symptoms, such as facial droop, dysarthria, and gait instability. Differential diagnosis of PRES often includes rostral brainstem infarction, transient ischemic attack, infectious encephalopathy, and metabolic/toxic encephalopathy, which is evaluated in the description of the case. The most common presentation of RPLS/PRES includes altered mental status, drowsiness, seizure, vomiting, alterations in speech including dysarthria, and visual disturbance. The first signs noted are commonly lethargy and somnolence. In this case, the patient presented notably with initial symptoms of dysarthria of speech and facial droop, with serum hypomagnesemia in which symptoms corrected rapidly with the administration of intravenous magnesium sulfate.
Insights
Severe hypomagnesemia can cause Posterior Reversible Encephalopathy Syndrome (PRES), a rare neurological condition. Prompt magnesium replacement effectively treated PRES symptoms in a reported case, highlighting hypomagnesemia as a crucial underlying cause.
Area of Science:
- Neurology
- Radiology
- Nephrology
Background:
- Posterior Reversible Encephalopathy Syndrome (PRES), also known as Reversible Posterior Leukoencephalopathy Syndrome (RPLS), is a neurological condition characterized by white matter abnormalities, often linked to hypertension.
- While commonly associated with hypertension, PRES can have other underlying causes that require investigation.
- The association between hypomagnesemia and PRES is rarely documented, making it an underrecognized etiology.
Observation:
- This report details a patient who presented with PRES syndrome.
- The patient exhibited neurological symptoms such as dysarthria and facial droop, mimicking acute cerebrovascular events.
- Severe hypomagnesemia was identified as a significant laboratory finding in this patient.
Findings:
- The patient's PRES symptoms showed rapid improvement following magnesium replacement therapy.
- Magnetic Resonance Imaging (MRI) revealed symmetrical white matter signaling, typical of PRES.
- Serum magnesium levels were critically low, correlating with the onset of PRES symptoms.
Implications:
- Hypomagnesemia should be considered a potential underlying cause in patients diagnosed with PRES.
- Prompt diagnosis and treatment of hypomagnesemia are crucial for managing PRES and preventing neurological sequelae.
- This case underscores the importance of comprehensive metabolic screening in PRES patients to identify treatable conditions like hypomagnesemia.
More Related Videos
08:47Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
Published on: November 8, 2018
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists